{
    "clinical_study": {
        "@rank": "90685", 
        "arm_group": [
            {
                "arm_group_label": "Fixed-Combination Bimatoprost/Brimonidine", 
                "arm_group_type": "Experimental", 
                "description": "One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks."
            }, 
            {
                "arm_group_label": "Bimatoprost Ophthalmic Solution 0.01% and Vehicle", 
                "arm_group_type": "Active Comparator", 
                "description": "One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks."
            }, 
            {
                "arm_group_label": "Brimonidine Tartrate Ophthalmic Solution 0.2%", 
                "arm_group_type": "Active Comparator", 
                "description": "One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine\n      compared with LUMIGAN\u00ae and ALPHAGAN\u00ae in patients with chronic glaucoma or ocular\n      hypertension."
        }, 
        "brief_title": "A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of ocular hypertension or glaucoma\n\n          -  Requires intraocular pressure (IOP)-lowering therapy\n\n        Exclusion Criteria:\n\n          -  Cataract surgery in one eye\n\n          -  Ocular laser or intraocular surgery within 6 months\n\n          -  Refractive surgery in either eye\n\n          -  Anticipated use of contact lenses during the study\n\n          -  Expected use of artificial tears during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863953", 
            "org_study_id": "192024-082"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fixed-Combination Bimatoprost/Brimonidine", 
                "description": "One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.", 
                "intervention_name": "Fixed-Combination Bimatoprost/Brimonidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Bimatoprost Ophthalmic Solution 0.01% and Vehicle", 
                "description": "One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.", 
                "intervention_name": "Bimatoprost Ophthalmic Solution 0.01%", 
                "intervention_type": "Drug", 
                "other_name": "LUMIGAN"
            }, 
            {
                "arm_group_label": "Bimatoprost Ophthalmic Solution 0.01% and Vehicle", 
                "description": "One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.", 
                "intervention_name": "Vehicle Ophthalmic Solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Brimonidine Tartrate Ophthalmic Solution 0.2%", 
                "description": "One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.", 
                "intervention_name": "Brimonidine Tartrate Ophthalmic Solution 0.2%", 
                "intervention_type": "Drug", 
                "other_name": "ALPHAGAN"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Brimonidine", 
                "Bimatoprost", 
                "Cloprostenol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Newport Beach", 
                    "country": "United States", 
                    "state": "California"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 42"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863953"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Average Eye Mean Diurnal IOP", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 14"
            }, 
            {
                "measure": "Change from Baseline in Average Eye Mean Diurnal IOP", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 28"
            }, 
            {
                "measure": "Average Eye Mean Diurnal IOP", 
                "safety_issue": "No", 
                "time_frame": "Day 14, Day 28, Day 42"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}